State Street SPDR S&P Biotech ETFXBI
Closing prices as of Oct 26, 2026Updated once daily after the US close — not a live quote.

$150.44

-2.54% past month

Notable price movement

  • Oct 26, 2026

    $150.47+0.62%

  • Oct 23, 2026

    $149.54-1.38%

  • Oct 22, 2026

    $151.64-0.75%

  • Oct 21, 2026

    $152.78-0.30%

  • Oct 20, 2026

    $153.24+3.64%

    The shares rose 3.64% while the broad market, measured by the S&P 500 ETF (SPY), rose only 0.34% . The move was therefore largely not shared by the broad market .

  • Oct 19, 2026

    $147.86+2.45%

    The shares rose 2.45%, while the S&P 500 ETF (SPY) moved only +0.42% in the same session . The move was therefore largely not shared by the broad market .

  • Oct 16, 2026

    $144.32-3.65%

    The broad market, as measured by the S&P 500 ETF (SPY), fell 1.11% on the same session in which this fund fell 3.65% . The decline therefore came alongside a broad-market drop, though it was roughly three times as large as the market's move .

Closing prices for XBI. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Recent news

Seeking Alpha22 hours agoCIO Weekly: 3 Tests To The Equities RallyThe Motley Fool4 days agoBiotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?Seeking AlphaOct 16, 2026AI Bubble: It's Not One Bubble, But Three Ready To BurstThe Motley FoolOct 5, 2026Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting BiotechSeeking AlphaOct 11, 2026BridgeBio reports improved symptoms in Phase 3 trial of rare-disease drugThe Motley FoolOct 4, 2026Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.

Prices and financial data are historical and provided for research only. Not investment advice.